About the CELLSEARCH® System
A question-and-answer guide to the CELLSEARCH® System—What it is, how it works, and how it can benefit the management of patients in your practice
The CELLSEARCH® System is the first standardized, FDA-cleared, semi-automated system that captures, isolates, and enumerates circulating tumor cells (CTCs) with a high level of sensitivity and specificity.1
- CELLSEARCH® Circulating Tumor Cell Kit (Epithelial) Instructions for Use. Janssen Diagnostics, LLC.
The CELLSEARCH® CTC Test can provide important information about disease status based on predictive prognosis to provide information to assist in clinical decisions.
The number of CTCs in patients with metastatic breast, prostate*, or colorectal cancer can predict favorable or unfavorable prognosis at initiation of and over the course of disease.
*Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer. For more information on the intended use and limitations for the CELLSEARCH® Circulating Tumor Cell Test, please refer to the Instructions for Use which can be found at documents.cellsearchctc.com.
Serial testing of CTCs should be used in conjunction with other clinical methods, such as imaging, lab tests, physical examination, and complete medical history. This aggregate of information can be used to assess patient status to provide information to assist in clinical decisions.